Novo Nordisk ADR’s (NVO) Stock: A 61.03% Annual Performance Rate

In the past week, NVO stock has gone up by 5.91%, with a monthly gain of 11.64% and a quarterly surge of 9.44%. The volatility ratio for the week is 1.83%, and the volatility levels for the last 30 days are 1.60% for Novo Nordisk ADR The simple moving average for the past 20 days is 6.25% for NVO’s stock, with a 28.32% simple moving average for the past 200 days.

Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?

Novo Nordisk ADR (NYSE: NVO) has a price-to-earnings ratio that is above its average at 49.60x. The stock has a 36-month beta value of 0.41. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for NVO is 3.34B, and at present, short sellers hold a 0.11% of that float. On June 11, 2024, the average trading volume of NVO was 4.08M shares.

NVO) stock’s latest price update

The stock price of Novo Nordisk ADR (NYSE: NVO) has jumped by 0.52 compared to previous close of 142.88. Despite this, the company has seen a gain of 5.91% in its stock price over the last five trading days. zacks.com reported 2024-06-10 that Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Analysts’ Opinion of NVO

Many brokerage firms have already submitted their reports for NVO stocks, with Goldman repeating the rating for NVO by listing it as a “Buy.” The predicted price for NVO in the upcoming period, according to Goldman is $156 based on the research report published on May 30, 2024 of the current year 2024.

BMO Capital Markets, on the other hand, stated in their research note that they expect to see NVO reach a price target of $163. The rating they have provided for NVO stocks is “Outperform” according to the report published on April 12th, 2024.

Morgan Stanley gave a rating of “Overweight” to NVO, setting the target price at $120 in the report published on January 23rd of the current year.

NVO Trading at 10.85% from the 50-Day Moving Average

After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.07% of loss for the given period.

Volatility was left at 1.60%, however, over the last 30 days, the volatility rate increased by 1.83%, as shares surge +11.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.86% upper at present.

During the last 5 trading sessions, NVO rose by +5.91%, which changed the moving average for the period of 200-days by +51.16% in comparison to the 20-day moving average, which settled at $135.95. In addition, Novo Nordisk ADR saw 38.84% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for NVO

Current profitability levels for the company are sitting at:

  • 0.45 for the present operating margin
  • 0.85 for the gross margin

The net margin for Novo Nordisk ADR stands at 0.37. The total capital return value is set at 0.82. Equity return is now at value 99.99, with 32.56 for asset returns.

Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at 3.47. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 45.41.

Currently, EBITDA for the company is 112.94 billion with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 18.17. The receivables turnover for the company is 3.87for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.70.

Conclusion

To sum up, Novo Nordisk ADR (NVO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts